Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKCA NASDAQ:ARVN NASDAQ:FTSV NASDAQ:INSM NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AARVNArvinas$9.78+0.6%$8.17$5.90▼$29.61$717.97M2.392.15 million shs59,128 shsFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AINSMInsmed$165.55-1.4%$144.48$60.40▼$168.21$34.98B1.032.66 million shs49,717 shsPCRXPacira BioSciences$21.04-8.6%$25.33$16.00▼$27.64$945.19M0.4750,328 shs538,615 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ARVNArvinas+2.10%-0.82%+29.26%+28.23%-64.15%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%INSMInsmed+1.30%+2.42%+15.99%+63.15%+125.26%PCRXPacira BioSciences+0.66%+3.41%-13.65%+2.63%+31.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AARVNArvinas$9.78+0.6%$8.17$5.90▼$29.61$717.97M2.392.15 million shs59,128 shsFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AINSMInsmed$165.55-1.4%$144.48$60.40▼$168.21$34.98B1.032.66 million shs49,717 shsPCRXPacira BioSciences$21.04-8.6%$25.33$16.00▼$27.64$945.19M0.4750,328 shs538,615 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ARVNArvinas+2.10%-0.82%+29.26%+28.23%-64.15%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%INSMInsmed+1.30%+2.42%+15.99%+63.15%+125.26%PCRXPacira BioSciences+0.66%+3.41%-13.65%+2.63%+31.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKCAAkcea Therapeutics 0.00N/AN/AN/AARVNArvinas 2.43Hold$16.1865.48% UpsideFTSVForty Seven 0.00N/AN/AN/AINSMInsmed 2.86Moderate Buy$152.88-7.66% DownsidePCRXPacira BioSciences 2.43Hold$33.4058.77% UpsideCurrent Analyst Ratings BreakdownLatest INSM, AKCA, FTSV, PCRX, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$171.0010/15/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$8.00 ➝ $6.0010/15/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$8.00 ➝ $6.0010/14/2025INSMInsmedUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $194.0010/8/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025INSMInsmedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PCRXPacira BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/7/2025ARVNArvinasPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$16.0010/3/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$121.00 ➝ $196.0010/2/2025INSMInsmedCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/2/2025INSMInsmedTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$154.00 ➝ $193.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14ARVNArvinas$263.40M2.73N/AN/A$8.17 per share1.20FTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70INSMInsmed$398.11M87.90N/AN/A$1.60 per share103.47PCRXPacira BioSciences$700.97M1.35$3.97 per share5.30$16.86 per share1.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/AARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)FTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/AINSMInsmed-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.78N/A8.19N/A-18.08%13.29%6.61%11/5/2025 (Estimated)Latest INSM, AKCA, FTSV, PCRX, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025PCRXPacira BioSciences$0.66N/AN/AN/A$182.86 millionN/A10/30/2025Q3 2025INSMInsmed-$1.35N/AN/AN/A$114.33 millionN/A10/29/2025Q3 2025ARVNArvinas-$0.74N/AN/AN/A$29.36 millionN/A8/7/2025Q2 2025INSMInsmed-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKCAAkcea TherapeuticsN/A12.1711.78ARVNArvinasN/A5.645.64FTSVForty SevenN/A14.8114.81INSMInsmed0.456.686.33PCRXPacira BioSciences0.502.381.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKCAAkcea Therapeutics19.27%ARVNArvinas95.19%FTSVForty Seven71.77%INSMInsmedN/APCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipAKCAAkcea Therapeutics1.50%ARVNArvinas4.73%FTSVForty Seven37.40%INSMInsmed3.00%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableARVNArvinas42073.42 million69.95 millionOptionableFTSVForty Seven5748.16 millionN/ANot OptionableINSMInsmed1,271211.38 million205.03 millionOptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionableINSM, AKCA, FTSV, PCRX, and ARVN HeadlinesRecent News About These CompaniesPacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®1 hour ago | markets.businessinsider.comPacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®2 hours ago | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by Analysts5 hours ago | marketbeat.comPacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene TherapyOctober 20 at 4:01 PM | globenewswire.comEasterly Investment Partners LLC Boosts Holdings in Pacira BioSciences, Inc. $PCRXOctober 17, 2025 | marketbeat.comKLP Kapitalforvaltning AS Increases Stake in Pacira BioSciences, Inc. $PCRXOctober 16, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Given "Sell (D)" Rating at Weiss RatingsOctober 10, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Gagnon Securities LLCOctober 8, 2025 | marketbeat.comGagnon Advisors LLC Has $5.10 Million Position in Pacira BioSciences, Inc. $PCRXOctober 8, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Has $1.29 Million Holdings in Pacira BioSciences, Inc. $PCRXOctober 8, 2025 | marketbeat.comGreenwood Capital Associates LLC Takes $314,000 Position in Pacira BioSciences, Inc. $PCRXOctober 4, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of "Moderate Buy" by AnalystsSeptember 26, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $11.54 Million Stock Holdings in Pacira BioSciences, Inc. $PCRXSeptember 23, 2025 | marketbeat.comPacira BioSciences (PCRX): Evaluating Valuation After Recent Share Price MomentumSeptember 17, 2025 | finance.yahoo.comPacira reports inducement grants under Nasdaq listing ruleSeptember 6, 2025 | msn.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comMarcelo Bigal Sells 4,912 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockAugust 12, 2025 | insidertrades.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | msn.comPacira (PCRX) Q2 Revenue Rises 1.7%August 6, 2025 | aol.comAPacira outlines narrowed $730M–$750M revenue guidance and increased margin targets as J&J ZILRETTA partnership takes shapeAugust 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINSM, AKCA, FTSV, PCRX, and ARVN Company DescriptionsAkcea Therapeutics NASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Arvinas NASDAQ:ARVN$9.78 +0.06 (+0.62%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Forty Seven NASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Insmed NASDAQ:INSM$165.55 -2.36 (-1.41%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Pacira BioSciences NASDAQ:PCRX$21.04 -1.98 (-8.61%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
